세계의 당뇨병성 케톤산증(DKA) 시장 보고서(2025년)

Diabetic ketoacidosis (DKA) is a serious complication of diabetes in which the body produces excessive blood acids known as ketones due to inadequate insulin levels. This condition can lead to dehydration, electrolyte imbalances, and potentially life-threatening complications. It is essential for diagnosing and managing severe metabolic imbalances in diabetic patients to prevent risks such as dehydration, organ failure, and coma.

The primary types of diabetic ketoacidosis (DKA) include pediatric diabetic ketoacidosis and adult diabetic ketoacidosis. Pediatric DKA occurs in children and adolescents with diabetes and is often triggered by insulin deficiency, infections, or other stress factors. Treatment options involve fluid replacement, electrolyte replenishment, and insulin therapy, including intermediate-acting and long-acting insulin. The available administration routes include oral, parenteral, and other methods. These treatments are distributed through various channels, both online and offline, and are utilized by multiple end users, such as hospitals, ambulatory care centers, and specialty clinics.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The diabetic ketoacidosis (DKA) market research report is one of a series of new reports from The Business Research Company that provides diabetic ketoacidosis (DKA) market statistics, including diabetic ketoacidosis (DKA) industry global market size, regional shares, competitors with diabetic ketoacidosis (DKA) market share, detailed diabetic ketoacidosis (DKA) market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic ketoacidosis (DKA) industry. This diabetic ketoacidosis (DKA) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diabetic ketoacidosis (dka) market size has grown strongly in recent years. It will grow from $2.9 billion in 2024 to $3.15 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increased diabetes prevalence, delayed diagnosis of type 1 diabetes, insufficient insulin therapy adherence, increased obesity rates, and lack of diabetes education programs.

The diabetic ketoacidosis (dka) market size is expected to see strong growth in the next few years. It will grow to $4.34 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to advancements in insulin delivery systems, increasing adoption of continuous glucose monitoring, growing awareness of diabetes complications, expansion of telemedicine for diabetes management, and rising healthcare expenditure. Major trends in the forecast period include the integration of artificial intelligence in diabetes care, the development of closed-loop insulin delivery systems, personalized medicine, advanced technologies, and innovative therapies.

The forecast of 8.4% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for the U.S. by restricting access to continuous insulin infusion pumps and rapid-acting analog cartridges imported from Denmark and France, potentially compromising emergency care and increasing ICU costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of obesity is contributing to the expansion of the diabetic ketoacidosis (DKA) market. Obesity is a medical condition characterized by excessive accumulation of body fat, which can have adverse health effects and increase the risk of various diseases. The increase in obesity rates is driven by several factors, including unhealthy diets rich in processed foods, sugars, and fats, sedentary lifestyles with limited physical activity, prolonged screen time, and socioeconomic challenges such as limited access to affordable healthy food and healthcare. Obesity heightens the risk of diabetic ketoacidosis (DKA) by promoting insulin resistance and leading to the development of type 2 diabetes, which can result in poor blood sugar control and subsequent DKA episodes. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately one in eight people worldwide were affected by obesity. This included 2.5 billion adults (aged 18 and older) who were overweight, with 890 million classified as obese. Among adults, 43% were overweight, and 16% were obese. Additionally, the number of overweight children under the age of five reached 37 million. Consequently, the growing prevalence of obesity is driving the expansion of the diabetic ketoacidosis market.

Leading companies in the diabetic ketoacidosis market are prioritizing the development of advanced technologies, such as continuous glucose monitoring tools, to enhance early detection, improve blood glucose and ketone level management, and ultimately reduce the frequency and severity of DKA episodes in individuals with diabetes. Continuous glucose monitoring (CGM) tools are devices designed to track glucose levels in real time, allowing individuals with diabetes to monitor and regulate their blood sugar levels effectively. For instance, in June 2022, Abbott Laboratories, a US-based medical device company, introduced an innovative continuous glucose-ketone monitoring system that enables real-time tracking of both glucose and ketone levels. This system integrates glucose and ketone monitoring, offering a comprehensive view of a patient's metabolic state. By measuring both metrics simultaneously, it facilitates the early detection of potential diabetic complications, such as diabetic ketoacidosis (DKA), before they become critical. Designed for continuous monitoring, the system provides frequent data updates without requiring manual testing, ensuring greater convenience for users.

In September 2023, Abbott Laboratories, a US-based medical device company, acquired Bigfoot Biomedical for an undisclosed amount. This acquisition strengthens Abbott's diabetic care portfolio, which already features the globally recognized FreeStyle Libre continuous glucose monitoring technology. Bigfoot Biomedical Inc. is a US-based company specializing in medical technology for diabetic care.

Major players in the diabetic ketoacidosis (DKA) market are Merck And Co. Inc., Pfizer Inc., Sanofi S.A., Bristol Myers Squibb, Novartis AG, Roche Holding AG, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., B. Braun Medical Inc., Fresenius Kabi, Merit Pharmaceutical, Oramed Pharmaceuticals Inc., ICU Medical Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., Wockhardt Ltd., Biocon Limited.

North America was the largest region in the diabetic ketoacidosis (DKA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diabetic ketoacidosis (DKA) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the diabetic ketoacidosis (DKA) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diabetic ketoacidosis (DKA) market includes revenues earned by entities by providing services such as blood glucose monitoring, ketone testing, and arterial blood gas analysis and related products such as blood glucose monitors, continuous glucose monitoring (CGM) devices, syringes, insulin pens, and insulin pumps. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diabetic Ketoacidosis (DKA) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diabetic ketoacidosis (dka) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for diabetic ketoacidosis (dka) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The diabetic ketoacidosis (dka) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Pediatric Diabetic Ketoacidosis, Adult Diabetic Ketoacidosis
• 2) By Treatment Type: Fluid Replacement, Electrolyte Replacement, Insulin Therapy, Intermediate-Acting Insulin, Long-Acting Insulin
• 3) By Route of Administration: Oral, Parenteral, Other
• 4) By Distribution Channel: Online Channel, Offline Channel
• 5) By End Use: Hospitals, Ambulatory Care Center, Specialty Clinics
• Subsegments:
• 1) By Pediatric Diabetic Ketoacidosis: Mild Pediatric DKA; Moderate Pediatric DKA; Severe Pediatric DKA
• 2) By Adult Diabetic Ketoacidosis: Mild Adult DKA; Moderate Adult DKA; Severe Adult DKA
• Companies Mentioned: Merck And Co. Inc.; Pfizer Inc.; Sanofi S.A.; Bristol Myers Squibb; Novartis AG; Roche Holding AG; GlaxoSmithKline plc; Eli Lilly and Company; Boehringer Ingelheim International GmbH; Novo Nordisk A/S; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; B. Braun Medical Inc.; Fresenius Kabi; Merit Pharmaceutical; Oramed Pharmaceuticals Inc.; ICU Medical Inc.; Tonghua Dongbao Pharmaceutical Co. Ltd.; Wockhardt Ltd.; Biocon Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Diabetic Ketoacidosis (DKA) Market Characteristics

3. Diabetic Ketoacidosis (DKA) Market Trends And Strategies

4. Diabetic Ketoacidosis (DKA) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Diabetic Ketoacidosis (DKA) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Diabetic Ketoacidosis (DKA) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Diabetic Ketoacidosis (DKA) Market Growth Rate Analysis
• 5.4. Global Diabetic Ketoacidosis (DKA) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Diabetic Ketoacidosis (DKA) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Diabetic Ketoacidosis (DKA) Total Addressable Market (TAM)

6. Diabetic Ketoacidosis (DKA) Market Segmentation

• 6.1. Global Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric Diabetic Ketoacidosis
• Adult Diabetic Ketoacidosis
• 6.2. Global Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fluid Replacement
• Electrolyte Replacement
• Insulin Therapy
• Intermediate-Acting Insulin
• Long-Acting Insulin
• 6.3. Global Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes of Administration
• 6.4. Global Diabetic Ketoacidosis (DKA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Online Channel
• Offline Channel
• 6.5. Global Diabetic Ketoacidosis (DKA) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Care Center
• Specialty Clinics
• 6.6. Global Diabetic Ketoacidosis (DKA) Market, Sub-Segmentation Of Pediatric Diabetic Ketoacidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild Pediatric DKA
• Moderate Pediatric DKA
• Severe Pediatric DKA
• 6.7. Global Diabetic Ketoacidosis (DKA) Market, Sub-Segmentation Of Adult Diabetic Ketoacidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild Adult DKA
• Moderate Adult DKA
• Severe Adult DKA

7. Diabetic Ketoacidosis (DKA) Market Regional And Country Analysis

• 7.1. Global Diabetic Ketoacidosis (DKA) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Diabetic Ketoacidosis (DKA) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Diabetic Ketoacidosis (DKA) Market

• 8.1. Asia-Pacific Diabetic Ketoacidosis (DKA) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Diabetic Ketoacidosis (DKA) Market

• 9.1. China Diabetic Ketoacidosis (DKA) Market Overview
• 9.2. China Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Diabetic Ketoacidosis (DKA) Market

• 10.1. India Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Diabetic Ketoacidosis (DKA) Market

• 11.1. Japan Diabetic Ketoacidosis (DKA) Market Overview
• 11.2. Japan Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Diabetic Ketoacidosis (DKA) Market

• 12.1. Australia Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Diabetic Ketoacidosis (DKA) Market

• 13.1. Indonesia Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Diabetic Ketoacidosis (DKA) Market

• 14.1. South Korea Diabetic Ketoacidosis (DKA) Market Overview
• 14.2. South Korea Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Diabetic Ketoacidosis (DKA) Market

• 15.1. Western Europe Diabetic Ketoacidosis (DKA) Market Overview
• 15.2. Western Europe Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Diabetic Ketoacidosis (DKA) Market

• 16.1. UK Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Diabetic Ketoacidosis (DKA) Market

• 17.1. Germany Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Diabetic Ketoacidosis (DKA) Market

• 18.1. France Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Diabetic Ketoacidosis (DKA) Market

• 19.1. Italy Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Diabetic Ketoacidosis (DKA) Market

• 20.1. Spain Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Diabetic Ketoacidosis (DKA) Market

• 21.1. Eastern Europe Diabetic Ketoacidosis (DKA) Market Overview
• 21.2. Eastern Europe Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Diabetic Ketoacidosis (DKA) Market

• 22.1. Russia Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Diabetic Ketoacidosis (DKA) Market

• 23.1. North America Diabetic Ketoacidosis (DKA) Market Overview
• 23.2. North America Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Diabetic Ketoacidosis (DKA) Market

• 24.1. USA Diabetic Ketoacidosis (DKA) Market Overview
• 24.2. USA Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Diabetic Ketoacidosis (DKA) Market

• 25.1. Canada Diabetic Ketoacidosis (DKA) Market Overview
• 25.2. Canada Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Diabetic Ketoacidosis (DKA) Market

• 26.1. South America Diabetic Ketoacidosis (DKA) Market Overview
• 26.2. South America Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Diabetic Ketoacidosis (DKA) Market

• 27.1. Brazil Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Diabetic Ketoacidosis (DKA) Market

• 28.1. Middle East Diabetic Ketoacidosis (DKA) Market Overview
• 28.2. Middle East Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Diabetic Ketoacidosis (DKA) Market

• 29.1. Africa Diabetic Ketoacidosis (DKA) Market Overview
• 29.2. Africa Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Diabetic Ketoacidosis (DKA) Market Competitive Landscape And Company Profiles

• 30.1. Diabetic Ketoacidosis (DKA) Market Competitive Landscape
• 30.2. Diabetic Ketoacidosis (DKA) Market Company Profiles
  • 30.2.1. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Diabetic Ketoacidosis (DKA) Market Other Major And Innovative Companies

• 31.1. Roche Holding AG
• 31.2. GlaxoSmithKline plc
• 31.3. Eli Lilly and Company
• 31.4. Boehringer Ingelheim International GmbH
• 31.5. Novo Nordisk A/S
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Regeneron Pharmaceuticals Inc.
• 31.8. B. Braun Medical Inc.
• 31.9. Fresenius Kabi
• 31.10. Merit Pharmaceutical
• 31.11. Oramed Pharmaceuticals Inc.
• 31.12. ICU Medical Inc.
• 31.13. Tonghua Dongbao Pharmaceutical Co. Ltd.
• 31.14. Wockhardt Ltd.
• 31.15. Biocon Limited

32. Global Diabetic Ketoacidosis (DKA) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Diabetic Ketoacidosis (DKA) Market

34. Recent Developments In The Diabetic Ketoacidosis (DKA) Market

35. Diabetic Ketoacidosis (DKA) Market High Potential Countries, Segments and Strategies

• 35.1 Diabetic Ketoacidosis (DKA) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Diabetic Ketoacidosis (DKA) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Diabetic Ketoacidosis (DKA) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer